Praxis touts ‘best-in-disease’ epilepsy data, but shares dip
Praxis Precision Medicines announced positive topline results from the Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures, reporting a 56.3% median reduction in seizure frequency over 8 weeks135.
22% of patients achieved complete seizure freedom during the last 28 days of treatment in the study13.
More than 54% of patients saw a 50% or greater reduction in seizures within the first week, with this benefit sustained throughout the trial13.
Vormatrigine showed a favorable safety profile, did not require titration (dose adjustment), and is intended as a once-daily oral treatment with no food restrictions1.
Despite the strong clinical results—touted by Praxis as 'best-in-disease'—the company's stock price declined following the announcement25.
Praxis plans to complete its pivotal POWER1 trial in Q4 2025 and begin enrollment for the POWER2 trial, with full data presentations planned at major epilepsy conferences later in the year14.
Sources:
1. https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-announces-positive-best-in-disease-8zpczmczhae2.html
2. https://firstwordpharma.com/story/5986158
3. https://www.clinicaltrialsarena.com/news/praxis-vormatrigine-eliminates-seizures-in-22-of-patients-in-phase-ii-trial/
4. https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-best-in-disease-topline-results-in-patients-with-focal-onset-seizures-from-the-radiant-study-of-vormatrigine
5. https://www.biopharmadive.com/news/praxis-epilepsy-data-trial-ion-channel/756709/